Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
Core Innovation
The invention provides humanized anti-PD-L1 antagonist monoclonal antibodies and antigen-binding portions that specifically bind human PD-L1. The antibodies are defined by heavy chain variable region CDR1, CDR2, and CDR3 comprising specified SEQ ID NO sequences, and by light chain variable region CDR1, CDR2, and CDR3 comprising specified SEQ ID NO sequences.
The invention also provides binding molecules that block human PD-L1/PD-1 interaction and are characterized for binding to PD-L1 on cells and PD-1 blocking activity. The described functional immune assays report anti-tumor immune response stimulation, including IL-2 and IFN-b3 secretion in PBMC assays and recall response measurements.
In addition, the invention includes antibody engineering and format considerations and sequence definition details. The antibodies include full-length IgG isotypes and antibody fragments, including antigen-binding portions and antibody formats including bispecifics, and the document supplies corresponding sequence listing entries for mouse, humanized CDR sequences, variable domains, and heavy/light chain sequences.
Claims Coverage
The independent claims define multiple groups of monoclonal antibodies or antigen-binding portions for specific binding to human PD-L1, with inventive features centered on specified CDR sequences or specified heavy/light variable region sequence selections, and in some cases sequence-identity thresholds or antibody format or immunoglobulin class constraints. Across the independent claims, the key inventive features are the use of particular SEQ ID NO-defined CDRs or variable-region sequence selections that confer specific binding to human PD-L1.
Cdr-defined human pd-l1 binding monoclonal antibody with seq id nos
A monoclonal antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region CDR1 comprising SEQ ID NO:31; a heavy chain variable region CDR2 comprising SEQ ID NO:37; a heavy chain variable region CDR3 comprising SEQ ID NO:43; a light chain variable region CDR1 comprising SEQ ID NO:13; a light chain variable region CDR2 comprising SEQ ID NO:19; and a light chain variable region CDR3 comprising SEQ ID NO:25, wherein said antibody or portion specifically binds to human PD-L1.
Cdr-defined human pd-l1 binding monoclonal antibody with seq id nos
A monoclonal antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region CDR1 comprising SEQ ID NO:32; a heavy chain variable region CDR2 comprising SEQ ID NO:38; a heavy chain variable region CDR3 comprising SEQ ID NO:44; a light chain variable region CDR1 comprising SEQ ID NO:14; a light chain variable region CDR2 comprising SEQ ID NO:20; and a light chain variable region CDR3 comprising SEQ ID NO:26, wherein said antibody or portion specifically binds to human PD-L1.
Cdr-defined human pd-l1 binding monoclonal antibody with seq id nos
A monoclonal antibody, or an antigen-binding portion thereof, comprising a heavy chain variable region CDR1 comprising SEQ ID NO:33; a heavy chain variable region CDR2 comprising SEQ ID NO:39; a heavy chain variable region CDR3 comprising SEQ ID NO:45; a light chain variable region CDR1 comprising SEQ ID NO:15; a light chain variable region CDR2 comprising SEQ ID NO:21; and a light chain variable region CDR3 comprising SEQ ID NO:27, wherein said antibody or portion specifically binds to human PD-L1.
High-identity heavy chain variable region sequence relative to seq id no:8
The monoclonal antibody, or an antigen-binding portion thereof, of 2, which comprises a heavy chain variable region comprising an amino acid sequence that has at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence as set forth in SEQ ID NO:8.
Selected heavy chain and light chain variable region sequences
A monoclonal antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-67 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 49-51.
Selected heavy chain and light chain variable region sequences
A monoclonal antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 68-70 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 55-58.
Selected heavy chain and light chain variable region sequences
A monoclonal antibody, or antigen-binding portion thereof, comprising: a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 71-76 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 59-61.
Overall, the independent claims cover PD-L1-specific monoclonal antibodies defined by specified heavy/light CDR sequences or by selected heavy/light variable region amino acid sequences from defined SEQ ID NO groups. In at least one independent-claim family, the coverage additionally requires a heavy chain variable region with identity thresholds relative to a reference sequence.
Stated Advantages
Stimulation of anti-tumor immune responses.
Protein thermal stability is characterized.
Documented Applications
Treatment of cancer.
Treatment of infectious disease.
Binding characterization involving PD-L1 on cells and PD-1 blocking.
Functional immune assays reporting IL-2 and IFN-b3 secretion in PBMC assays, including recall responses.
Interested in licensing this patent?